Did You Know.... 🌍 About 1% of people worldwide, which is around 76 million, have vitiligo. There are over 20 ongoing studies trying to find better treatments for this condition, showing a big need for new and improved therapies. 🔍 Current methods to measure treatment effectiveness have significant limitations due to their reliance on subjective scoring systems for evaluating pigmentation. These imprecise systems delay drug development and hinder new treatment progress. Newtone Technologies, part of QIMA's Life Sciences division, has now created a tool called the "Vitil-IA algorithm" to address these issues. This tool shows promise for improving future clinical trials. The Vitil-IA algorithm: • Provides highly accurate and precise measurements. • Ensures excellent consistency, reducing problems caused by different positions and operators. • Requires minimal human intervention. To learn more about this new automated method that could change vitiligo clinical trials, watch Jean-Michel Delaval's latest video on Vitil-IA® 🔽 https://lnkd.in/e4XuBQqV #lifesciences #vitiligo #clinicaltrials
Current vitiligo scoring systems lack precision and present limited resolution, slowing down drug development times. But what if we could change that? Join Jean-Michel Delaval in our latest video to learn everything about Vitil-IA®, a new automated method designed to revolutionize vitiligo clinical trials. 🖱 CLICK HERE TO ACCESS THE FULL VIDEO: https://lnkd.in/e4XuBQqV --- #LifeSciences #Innovation #Dermatology #Vitiligo Newtone Technologies
